Study design (if review, criteria of inclusion for studies)
Randomised and quasi-randomised controlled trials comparing pneumococcal vaccination (with either a polysaccharide or conjugate pneumococcal vaccine) with non-vaccination or placebo in children or adults with cystic fibrosis were eligible for inclusion
Participants
Children and adults with cystic fibrosis.
Interventions
Pneumococcal vaccination (with either a polysaccharide or conjugate pneumococcal vaccine) vs non-vaccination or placebo
Outcome measures
Primary outcomes: QoL, pulmonary exacerbation, need for hospitalisation, need for additional antibiotic therapy (oral, intravenous), infection with pneumococcus (invasive pneumococcal disease of vaccine-specific serotype)
Main results
There are no trials included in this review.
Authors' conclusions
As no trials were identified we cannot draw conclusions on the efficacy of routine pneumococcal immunisation in people with cystic fibrosis in reducing their morbidity or mortality. As many countries now include pneumococcal immunisation in their routine childhood vaccination schedule it is unlikely that future randomised controlled trials will be initiated. Rigorously conducted epidemiological studies may offer the opportunity to evaluate the efficacy of pneumococcal vaccination in reducing morbidity and mortality in people with cystic fibrosis.